PARK7-Mediated Delactylation of SF3B Reprograms RNA Splicing to Attenuate Fibrosis and Promote Antitumor Immunity.

PARK7-mediated delactylation of SF3B2 at K280 suppresses tumor growth and fibrosis, enhancing antitumor immunity in cancer.

• Why it matters: Understanding enzymes that regulate lactylation could reveal new therapeutic targets for cancer treatment, as lactylation influences tumor progression and immune responses.
• What they did: Using lactylome analysis and mass spectrometry, the study identified PARK7 as a delactylase that modifies SF3B2, affecting RNA splicing and tumor behavior in cancer models.
• The result: Elevated PARK7 levels are linked to better patient survival, and its activity limits tumor growth and fibrosis by reprogramming RNA splicing, offering potential avenues for cancer therapy.